Clinical Trial: Additional Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury

U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07722962) titled 'Additional Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury' on July 20.

Brief Summary: This is a Phase 3, multicenter, open-label, single-arm additional study to evaluate the efficacy of intrathecal KP-100IT in patients with acute spinal cord injury. Eligible patients will receive KP-100 0.6 mg/body by intrathecal administration once per week for a total of 5 doses and will be followed for approximately 24 weeks after the first dose.

Study Start Date: July 31

Study Type: INTERVENTIONAL

Condition: Acute Spinal Cord Injury (SCI)

Intervention: DRUG: KP-100IT

The contents of each vial were dissolved in the dis...